Blinatumomab

Recurrent Diffuse Large B-Cell Lymphoma

Amgenmonoclonal_antibodyPhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 73/ 100

Competitive context

108 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Selinexor Chengdu Zenitar Biomedical Technology Co., Ltd	Phase 3	BB
DEXAMETHASONE City of Hope Medical Center	Phase 2/3	BB
Ifosfamide University of California, Davis	Phase 3	BB
Cyclophosphamide Nathan Denlinger	Phase 3	BB
Axicabtagene Ciloleucel Zhujiang Hospital	Phase 3	BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant

BBB

Indicative ·

72 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BBB

Indicative ·

72 / 100

Precursor B-Cell Acute Lymphoblastic LeukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.